Purpose

The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.

Condition

Eligibility

Eligible Ages
Between 18 Years and 100 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization. 2. Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II).

Exclusion Criteria

  1. Patients less than 18 years of age. 2. Pregnant women at the scheduled time of PA pressure sensor implant. 3. Patients unable or unwilling to have continuity of care in the heart failure clinic.

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Other
Time Perspective
Other

Arm Groups

ArmDescriptionAssigned Intervention
Retrospective arm Patients who underwent PA pressure implantation from January 1, 2019 will be identified for registry participation. Patients who were implanted before November 8, 2022 will be considered enrolled in the retrospective arm of the registry and may not need to consent if consent waiver is granted by the institutional IRB (Institutional Review Board).
  • Device: Observational
    We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
Prospective arm Patients will be identified as eligible for PA pressure sensor implant by a heart failure cardiologist. Patients will consent for device implant and procedure (right heart catheterization) as per standard of care. Patients may also consent to registry participation as per local institutional guidelines and requirements.
  • Device: Observational
    We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.

Recruiting Locations

Scripps Health
La Jolla, California 92037
Contact:
Timothy Jordan, MD

Indiana University
Bloomington, Indiana 47401
Contact:
Maya Guglin, MD

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Kartik Munshi, MPH
kmunshi@kumc.edu

Minneapolis Heart Institute Foundation/ Allina Health
Minneapolis, Minnesota 55407
Contact:
Sarah Schwager, RN

Saint Luke's Health System
Kansas City, Missouri 64131
Contact:
Timothy Fendler, MD

University of North Carolina/ Rex Hospital, Inc.
Raleigh, North Carolina 27607
Contact:
Elizabeth Volz, MD

Providence Heart Institute
Portland, Oregon 97225
Contact:
Christy Lenhart, RN

Prisma Health
Columbia, South Carolina 29203
Contact:
Suzanne Amaker

Sanford Health
Sioux Falls, South Dakota 57104
Contact:
Orvaar Jonsson, MD

Austin Heart
Austin, Texas 78756
Contact:
Kunjan Bhatt, MS

Houston Methodist DeBakey Heart and Vascular Center
Houston, Texas 77030
Contact:
Saba Khan

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Kartik Munshi, MPH
913-945-6445
kmunshi@kumc.edu

Detailed Description

Longitudinal, multi-center, and non-interventional registry. Patients will be identified as eligible for pulmonary artery pressure sensor implant by a heart failure cardiologist from the heart failure clinic. They will consent for device implant and procedure (right heart catheterization) per standard of care. Patients may also consent to the registry participation, which is optional. They will be informed that the registry intends to gather data and that they may be approached in the future for additional research based on their data and clinical situation. Additionally, patients who underwent pulmonary artery pressure sensor implantation from January 1, 2019, will be identified and consent will be obtained for registry participation, which is optional.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.